• Neuromedin S (rat): Product Overview

  2026-10-07

  Neuromedin S (rat), SKU B5466, is a supplier-described endogenous peptide agonist associated with neuromedin U receptor signaling. No matched paper evidence was supplied, so biological performance and assay suitability remain unverified.

• Separating Growth Arrest from Cell Death in Cancer

  2026-10-07

  Hannah Schwartz’s 2022 doctoral dissertation examines why conventional relative-viability measurements can obscure the distinct contributions of proliferation arrest and cell death. Its central contribution is a framework for interpreting anticancer drug responses as separable, time-dependent biological processes rather than as a single composite endpoint.

• 2'3'-cGAMP and the Next STING Frontier

  2026-10-06

  The next phase of cGAS-STING research will connect innate immune signaling with metabolic state. This thought-leadership analysis examines how 2'3'-cGAMP can serve as a defined STING-proximal research tool, while the 2025 D2HG biosensor study opens new questions about immune–metabolic feedback, translational biomarkers, and the limits of current evidence.

• GLP-1 (9-36) Amide: Evidence and Limits

  2026-10-06

  This source-grounded overview explains what GLP-1 (9-36) amide can and cannot establish in GLP-1 receptor signaling research. It separates supplier descriptions from findings in a 2019 study of glucagon–GLP-1 receptor crosstalk, while addressing evidence quality, interpretation, scope, and limitations.

• BIIE 0246 and the Adipose-Neural Axis

  2026-10-05

  BIIE 0246 is a selective neuropeptide Y Y2 receptor antagonist that can help clarify receptor-subtype logic in neuropeptide signaling. This article interprets its research value alongside new evidence linking adipose-neural communication to cardiac arrhythmia, while defining what the findings do—and do not—establish.

• PTH (1-34) Peptide: A Kidney Modeling Lens

  2026-10-05

  Parathyroid hormone (1-34) (human) offers a focused way to interrogate PTH/PTHrP receptor signaling across bone and kidney research. This article develops an evidence-based framework for interpreting the peptide alongside spatial kidney assembloids without overstating what either model can establish.

• GLP-1 (9-36) Amide: Evidence and Research Context

  2026-10-04

  GLP-1 (9-36) amide is marketed as a glucagon-like peptide-1 receptor antagonist for research, but the supplied primary study directly evaluates exendin(9-39) and related ligands rather than GLP-1 (9-36) amide itself. This overview places the peptide in the broader context of GLP-1 receptor signaling research, explains what the published evidence shows about receptor cross-reactivity, and defines the limits of translating in vitro cAMP findings to metabolic or therapeutic conclusions.

• 2'3'-cGAMP: From STING Signal to Metabolic Readout

  2026-10-03

  Explore how 2'3'-cGAMP can serve not only as a STING pathway stimulus but also as a mechanistic anchor for studying immune–metabolic signaling. This evidence-focused analysis connects cGAS-STING activation with D2HG biosensing while defining the limits of current evidence.

• 2-Deoxy-D-glucose: A Metabolic Assay Compass

  2026-10-02

  2-Deoxy-D-glucose is more than a glycolysis inhibitor: it is a causal probe for testing how metabolic state shapes cell phenotype. This article connects 2-DG assay design with macrophage metabolic reprogramming, cancer metabolism, and interpretation of translational experiments.

• Cyclo (-RGDfC) Workflow for Integrin Assays

  2026-10-01

  Cyclo (-RGDfC) supports practical αvβ3-focused workflows spanning cell adhesion, migration, angiogenesis research, and targeted delivery. This guide combines product-handling advice with assay controls inspired by a canine osteosarcoma viability study, helping researchers distinguish receptor-mediated effects from general cytotoxicity.

• Methyl-β-cyclodextrin: Practical Lab Guide

  2026-10-01

  Methyl-β-cyclodextrin (SKU C6939) is a biochemical reagent for membrane cholesterol extraction and controlled studies of membrane organization. It is intended for research workflows only; working concentrations, exposure conditions, and cell compatibility must be established for each assay rather than inferred from the product specification.

• Indazole/Indole Glucagon Receptor Antagonists

  2026-09-30

  Lin and colleagues reported a novel indazole- and indole-based series of glucagon receptor antagonists designed from the earlier MK-0893 scaffold, combining systematic SAR with promising in vitro, pharmacokinetic, and acute in vivo activity. The study also illustrates how HOBt-supported amide bond formation can be integrated into small-molecule medicinal chemistry routes.

• Z-YVAD-FMK: A Practical Caspase-1 Inhibitor Guide

  2026-09-30

  Z-YVAD-FMK enables pathway-resolved studies of caspase-1 activity, inflammatory cytokine release, apoptosis, and pyroptosis rather than relying on viability measurements alone. This guide translates product characteristics and a lung epithelial bystander-death study into practical assay design, controls, troubleshooting, and interpretation strategies.

• Parathyroid hormone (1-34) (human): Research Guide

  2026-09-29

  Parathyroid hormone (1-34) (human) is a bioactive PTH (1-34) peptide fragment for receptor-signaling, bone metabolism, and calcium-homeostasis studies. Its defined sequence, cAMP potency, solubility profile, and rat bone-mass findings support controlled use in osteoporosis model and kidney-disease research, but the reagent is not a clinical treatment.

• Cyclo (-RGDfC) for Spatial Integrin Assays

  2026-09-29

  Discover how Cyclo (-RGDfC) and c(RGDfC) can support spatially resolved integrin assays by combining αvβ3 recognition with open-platform hydrogel printing. This article translates recent OP-DLP advances into practical tumor targeting peptide workflows while separating established evidence from experimental recommendations.

8426 records 1/562 page Next 12345 下5页 Last page